Relmada Therapeutics (RLMD) Tops Q2 EPS by 6c

Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.84), $0.06 better than the analyst estimate of ($0.90).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Monolithic Power Systems (MPWR) Reiterated at Buy by Stifel on Reaching $4B Target
• Designer Brands Inc. (DBI) Tops Q2 EPS by 8c, Misses on Revenue; Offers FY27 EPS Guidance
• Driven Brands (DRVN) PT Raised to $18 at Canaccord